Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-11-09
2000-01-04
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514342, 514593, 514635, 514866, A61K 3144, A61K 31425, A61K 31175, A61K 31155
Patent
active
06011049&
ABSTRACT:
Combinations of a glitazone antidiabetic agent and a biguanide antidiabetic agent, and optionally a sulfonylurea antidiabetic agent, are useful for treating diabetes mellitus and improving glycemic control.
REFERENCES:
PCT International Search Report, PCT/US97/21996.
Oakes, et al., Diabetes, vol. 13:1203, 1994, A New Antidiabetic Agent, BRL 49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat.
Hulin, et al, Current Pharmaceutical Design 2:85-102, 1996, The Glitazone Family of Antidiabetic Agents.
Groop, M.D., Diabetes Care, 15:737-754, 1992, Sulfonylureas in NIDDM.
Nakano, et al., CS-045, Clinical Evaluation of a New Oral Hypoglycemic Drug, CS-045, on Daily Profile of Blood Glucose in Patients with Non-Insulin Dependent Diabetes Mellitus (1993).
Company News On-Call, 1-3, 1997 Rezulin.RTM. (troglitazone) Receives FDA Marketing Clearance for use as Either Initial or Combination Therapy for Type 2 Diabetes.
Spencer, et al., Drugs, vol. 54:89-101, 1997, Troglitazone.
Yamasaki, et al., The Tokohu Journal of Experimental Medicine, vol. 183:173-183, 1997, Pioglitazone (AD-4833) Ameliorates Insulin Resistance in Patients with NIDDM.
Iwamoto, et al., Diabetic Medicine, vol. 13:365-370, 1996, Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Alon.
Bressler & Johnson., Drugs& Aging, vol. 9:418-437, 1996, Oral Antidiabetic Drug Use in the Elderly.
Okaka, et al., Chemical Abstracts, vol. 126, No. 20, 1997, Abstract No. 258925, Antidiabetic Effects of Pioglitzone HCL Alone or in Combination with Insulin or Sylfonylurea in Diabetic Animals.
De Souza, et al., Diabetes, vol. 44:984-991, 1995, Insulin Secretory Defect in Zucker fa/fa Ratsis Improved by Ameliorating Insulin Resistance.
Ashbrook Charles W.
Jordan Kimberly
Warner-Lambert & Company
LandOfFree
Combinations for diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations for diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations for diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1072936